Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Mariana Kaplan · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · 2024 · $299,397 — We are close to finalizing the last visits for this study and analysis is ongoing. The study enrolled patients with a variety of autoimmune diseases including Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody (ANCA)-Associat…
Barry Okeefe · DIVISION OF BASIC SCIENCES - NCI · 2024 · $780,903 — As part of this project, the Protein Chemistry and Molecular Biology Section (PCMBS) has continued to discover new bioactive proteins including three new members of the reciting class of anti-cancer proteins and one new anti-SARS-CoV-2 and anti-his lectin, Dm-CVNH, a homolog of the protein cyanoviri…
Nadya Tarasova · DIVISION OF BASIC SCIENCES - NCI · 2024 · $32,788 — We have identified several inhibitors of STAT3 N-terminal domain that has been shown to mediate inflammatory effects of the virus, and contribute to "long COVID". The lead compound turned out to be stable in human plasma. However, its half life in the mouse plasma was less than 5 minutes. The later …
Adriaan Bax · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $658,712 — As applies for HIV-1, entry of SARS-CoV-2 into a host cell is also mediated by a Class I viral fusion protein: Spike. This protein, also referred to as S, is responsible for merging the viral and host cell membranes. Atomic resolution models for both the post-fusion 6-helix bundle (6HB) and the pre…
Faustine Williams · NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES · 2024 · $797,190 — In FY24, we continued to use nationally representative data to identify and understand the individual and structural factors influencing the mental health and well-being of immigrants under Objective 1. In the first study, we utilized the National Interview Survey (NHIS) from 2005-2018 cross-section…
MARC NICKLAUS · DIVISION OF BASIC SCIENCES - NCI · 2024 · $158,959 — In collaboration with several Principal Investigators at the CCR/NCI and NIH, in silico screening of large small-molecule databases are being conducted for a number of molecular targets relevant for cancer. We are using the CADD Group's resources, including our screening databases to generate lists …
Nicole Y Morgan · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $1,510,844 — The use of microfabricated and microfluidic structures in biomedical research continues to expand, but many research applications for these devices require customization, and new applications typically require several design iterations for troubleshooting and optimization. To help bring the necessar…
Heather Kalish · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · 2024 · $892,557 — Sub-project #1 MALDI imaging of tissue samples to identify novel proteins MALDI-TOF Imaging is an emerging tool for the label free measurement of peptides, proteins, lipids, drugs and metabolites. The tissue can be imaged directly be the MALDI-TOF and combined with other modalities to study the mo…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $705,216 — Interleukin-7 (IL-7) is the principal T-cell homeostatic factor in the body and is critical to reconstitute the normal T-lymphocyte pool when lymphopenia (loss of lymphocytes) occurs, as it happens in the course of infectious diseases (for example HIV/AIDS or COVID-19) or as a consequence of medical…
Clifton Barry · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,276,926 — (1) NIAID 15-I-N070: Radiologic and immunologic biomarkers to enhance early bactericidal activity (EBA) measurements of sterilizing drug activity in tuberculosis (NexGen EBA). This study hypothesized that drug regimens associated with higher sterilizing activity show distinct cytokine patterns and q…
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $6,531,361 — The mission of the ‘Disease Modeling and Transmission’ (DMT) section is to study emerging and re-emerging viral pathogens that cause hemorrhagic fever, encephalitis and respiratory distress, with an aim of developing diagnostics, treatments, and vaccines. The research objectives are to learn how to …
Amy Klion · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,075,838 — Using a cohort of more than 700 subjects with a wide variety of eosinophilic disorders, ranging from benign eosinophilia to eosinophilic leukemia, we have continued to identify and characterize novel subgroups of patients with eosinophilia and to explore responses to targeted therapies with the goal…
Katrin Mayer-Barber · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $105,946 — The lungs of patients suffering from severe Coronavirus Disease 2019 (COVID-19) present with pneumonia and significant tissue damage which can lead to acute respiratory distress syndrome (ARDS) and death. This tissue destruction is caused not only by the etiological, cytopathic Severe Acute Respirat…
Philip Murphy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $210,857 — The aim of this project is to test the hypothesis that specific chemokines and chemokine receptors drive either immunopathology or immune control of SARS-CoV-2 infection in a mouse model. The motivation for this aim is that chemokines regulate leukocyte trafficking and covid-19 disease pathogenesis …
Irini Sereti · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $162,051 — In order to evaluate the pathogenesis of COVID with a focus on lymphopenia, inflammation and coagulopathy, we have opened a protocol to obtain clinical samples (peripheral blood mononuclear cells, serum and plasma, nasal swabs) from people with active COVID-19 disease. In addition, recovered patient…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $133,896 — Following the success of our HIV-1 vaccine platform based on co-formulated Env+Gag mRNA in order to produce non-infectious VLPs (Zhang et al., Nat. Med. 27:2234, 2021), in collaboration with Moderna, Inc., we have designed a similar vaccine platform for SARS-CoV-2. The major results obtained thus fa…
Tovi Lehmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $731,182 — The spread of COVID-19 in rural sub-Saharan Africa is poorly understood and reliable data are unlikely to be obtained because of low capacity for disease surveillance, compounded by high proportion of young population that present mostly asymptomatic or low-symptomatic infections. To fill this gap a…
Pamela Frischmeyer-Guerrerio · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $369,941 — In FY24, we reported the primary clinical outcomes of our phase 2 randomized, double-blinded, placebo-controlled trial (COvid-19 Vaccine Associated Allergic Reactions trial; COVAAR) where 16 participants who previously reported an SAR to their first dose of a COVID-19 mRNA vaccine were randomly assi…
Mattia Bonsignori · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,670,518 — The human immune system generates a diverse repertoire of pathogen-binding proteins called antibodies secreted by terminally differentiated short- and long-lived plasma cells as well as antigen-experienced B cells which constitute a pool of memory B cells that can further mature upon re-engagement i…
William Elkins · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $46,528,760 — CMB Research Support Specialists provide technical expertise and support to NIAID Principal Investigators, assisting them with true cage to benchside support. Both pathology and technical proficiency resulted in numerous co-authorship opportunities. The CMB has successfully maintained a gnotobiot…